A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study

V. Chajès; N. Assi; C. Biessy; P. Ferrari; S. Rinaldi; N. Slimani; G. M. Lenoir; L. Baglietto; M. His; M. C. Boutron-Ruault; A. Trichopoulou; P. Lagiou; M. Katsoulis; R. Kaaks; T. Kühn; S. Panico; V. Pala; G. Masala; H. B. Bueno-de-Mesquita; P. H. Peeters; C. Van Gils; A. Hjartåker; K. Standahl Olsen; R. Borgund Barnung; A. Barricarte; D. Redondo-Sanchez; V. Menéndez; P. Amiano; M. Wennberg; T. Key; K. T. Khaw; M. A. Merritt; E. Riboli; M. J. Gunter; I. Romieu

doi:10.1093/annonc/mdx482

A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study

V. Chajès^*, N. Assi, C. Biessy, P. Ferrari, S. Rinaldi, N. Slimani, G. M. Lenoir, L. Baglietto, M. His, M. C. Boutron-Ruault, A. Trichopoulou, P. Lagiou, M. Katsoulis, R. Kaaks, T. Kühn, S. Panico, V. Pala, G. Masala, H. B. Bueno-de-Mesquita, P. H. PeetersC. Van Gils, A. Hjartåker, K. Standahl Olsen, R. Borgund Barnung, A. Barricarte, D. Redondo-Sanchez, V. Menéndez, P. Amiano, M. Wennberg, T. Key, K. T. Khaw, M. A. Merritt, E. Riboli, M. J. Gunter, I. Romieu

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting.

Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours.

Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4-Q1) 1.37; 95% confidence interval (CI), 1.14-1.64; P for trend=0.0001, q value=0.004] as well as a high desaturation index (DI₁₆) (16:1n-7/ 16:0) [OR (Q4-Q1), 1.28; 95% C, 1.07-1.54; P for trend=0.002, q value=0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3-T1)=2.01; 95% CI, 1.03-3.90; P for trend=0.047], whereas no association was found for ER-positive tumours (P-heterogeneity=0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor.

Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.

Original language	English
Pages (from-to)	2836-2842
Number of pages	7
Journal	Annals of Oncology
Volume	28
Issue number	11
Early online date	18 Sept 2017
DOIs	https://doi.org/10.1093/annonc/mdx482
Publication status	Published - 01 Nov 2017
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by World Cancer Research Funds and the Institut National du Cancer (INCA) (2015-163). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer (no grant numbers apply). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (2009/90), Statistics Netherlands (The Netherlands); UiT The Arctic University of Norway; Health Research Fund (FIS), PI13/00061 to Granada, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk) (UK) and INCA (2015-163).

Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Keywords

Biomarkers
Breast cancer
EPIC
Epidemiology
Fatty acids

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdx482Licence: Unspecified

Cite this

Chajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., Lenoir, G. M., Baglietto, L., His, M., Boutron-Ruault, M. C., Trichopoulou, A., Lagiou, P., Katsoulis, M., Kaaks, R., Kühn, T., Panico, S., Pala, V., Masala, G., Bueno-de-Mesquita, H. B., ... Romieu, I. (2017). A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. Annals of Oncology, 28(11), 2836-2842. https://doi.org/10.1093/annonc/mdx482

@article{629f72e00acb451f9af858b51f0053be,

title = "A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study",

abstract = "Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting. Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours. Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4-Q1) 1.37; 95% confidence interval (CI), 1.14-1.64; P for trend=0.0001, q value=0.004] as well as a high desaturation index (DI16) (16:1n-7/ 16:0) [OR (Q4-Q1), 1.28; 95% C, 1.07-1.54; P for trend=0.002, q value=0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3-T1)=2.01; 95% CI, 1.03-3.90; P for trend=0.047], whereas no association was found for ER-positive tumours (P-heterogeneity=0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor. Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.",

keywords = "Biomarkers, Breast cancer, EPIC, Epidemiology, Fatty acids",

author = "V. Chaj{\`e}s and N. Assi and C. Biessy and P. Ferrari and S. Rinaldi and N. Slimani and Lenoir, {G. M.} and L. Baglietto and M. His and Boutron-Ruault, {M. C.} and A. Trichopoulou and P. Lagiou and M. Katsoulis and R. Kaaks and T. K{\"u}hn and S. Panico and V. Pala and G. Masala and Bueno-de-Mesquita, {H. B.} and Peeters, {P. H.} and {Van Gils}, C. and A. Hjart{\aa}ker and {Standahl Olsen}, K. and {Borgund Barnung}, R. and A. Barricarte and D. Redondo-Sanchez and V. Men{\'e}ndez and P. Amiano and M. Wennberg and T. Key and Khaw, {K. T.} and Merritt, {M. A.} and E. Riboli and Gunter, {M. J.} and I. Romieu",

note = "Funding Information: This study was supported by World Cancer Research Funds and the Institut National du Cancer (INCA) (2015-163). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer (no grant numbers apply). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G{\'e}n{\'e}rale de l{\textquoteright}Education Nationale, Institut National de la Sant{\'e} et de la Recherche M{\'e}dicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (2009/90), Statistics Netherlands (The Netherlands); UiT The Arctic University of Norway; Health Research Fund (FIS), PI13/00061 to Granada, Regional Governments of Andaluc{\'i}a, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and County Councils of Sk{\aa}ne and V{\"a}sterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk) (UK) and INCA (2015-163). Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",

year = "2017",

month = nov,

day = "1",

doi = "10.1093/annonc/mdx482",

language = "English",

volume = "28",

pages = "2836--2842",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

Chajès, V, Assi, N, Biessy, C, Ferrari, P, Rinaldi, S, Slimani, N, Lenoir, GM, Baglietto, L, His, M, Boutron-Ruault, MC, Trichopoulou, A, Lagiou, P, Katsoulis, M, Kaaks, R, Kühn, T, Panico, S, Pala, V, Masala, G, Bueno-de-Mesquita, HB, Peeters, PH, Van Gils, C, Hjartåker, A, Standahl Olsen, K, Borgund Barnung, R, Barricarte, A, Redondo-Sanchez, D, Menéndez, V, Amiano, P, Wennberg, M, Key, T, Khaw, KT, Merritt, MA, Riboli, E, Gunter, MJ & Romieu, I 2017, 'A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study', Annals of Oncology, vol. 28, no. 11, pp. 2836-2842. https://doi.org/10.1093/annonc/mdx482

TY - JOUR

T1 - A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study

AU - Chajès, V.

AU - Assi, N.

AU - Biessy, C.

AU - Ferrari, P.

AU - Rinaldi, S.

AU - Slimani, N.

AU - Lenoir, G. M.

AU - Baglietto, L.

AU - His, M.

AU - Boutron-Ruault, M. C.

AU - Trichopoulou, A.

AU - Lagiou, P.

AU - Katsoulis, M.

AU - Kaaks, R.

AU - Kühn, T.

AU - Panico, S.

AU - Pala, V.

AU - Masala, G.

AU - Bueno-de-Mesquita, H. B.

AU - Peeters, P. H.

AU - Van Gils, C.

AU - Hjartåker, A.

AU - Standahl Olsen, K.

AU - Borgund Barnung, R.

AU - Barricarte, A.

AU - Redondo-Sanchez, D.

AU - Menéndez, V.

AU - Amiano, P.

AU - Wennberg, M.

AU - Key, T.

AU - Khaw, K. T.

AU - Merritt, M. A.

AU - Riboli, E.

AU - Gunter, M. J.

AU - Romieu, I.

N1 - Funding Information: This study was supported by World Cancer Research Funds and the Institut National du Cancer (INCA) (2015-163). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer (no grant numbers apply). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (2009/90), Statistics Netherlands (The Netherlands); UiT The Arctic University of Norway; Health Research Fund (FIS), PI13/00061 to Granada, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk) (UK) and INCA (2015-163). Publisher Copyright: © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting. Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours. Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4-Q1) 1.37; 95% confidence interval (CI), 1.14-1.64; P for trend=0.0001, q value=0.004] as well as a high desaturation index (DI16) (16:1n-7/ 16:0) [OR (Q4-Q1), 1.28; 95% C, 1.07-1.54; P for trend=0.002, q value=0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3-T1)=2.01; 95% CI, 1.03-3.90; P for trend=0.047], whereas no association was found for ER-positive tumours (P-heterogeneity=0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor. Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.

AB - Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting. Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours. Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4-Q1) 1.37; 95% confidence interval (CI), 1.14-1.64; P for trend=0.0001, q value=0.004] as well as a high desaturation index (DI16) (16:1n-7/ 16:0) [OR (Q4-Q1), 1.28; 95% C, 1.07-1.54; P for trend=0.002, q value=0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3-T1)=2.01; 95% CI, 1.03-3.90; P for trend=0.047], whereas no association was found for ER-positive tumours (P-heterogeneity=0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor. Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.

KW - Biomarkers

KW - Breast cancer

KW - EPIC

KW - Epidemiology

KW - Fatty acids

U2 - 10.1093/annonc/mdx482

DO - 10.1093/annonc/mdx482

M3 - Article

C2 - 28950350

AN - SCOPUS:85034055590

SN - 0923-7534

VL - 28

SP - 2836

EP - 2842

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this